Phosphate levels are critical for cellular energy and skeletal development and mineralization. FGF23 is a key phosphaturic hormone, dysregulated actions/levels of which are the cause of several inherited bone diseases. FGF23 elevation in response to phosphate retention also plays a key role in the pathogenesis of and complications related to renal failure. The mechanisms underlying the production of FGF23 are poorly understood, limiting the ability to develop effective treatments for these disorders. XL?s is a G protein alpha-subunit, genetic alterations of which are associated with multiple human diseases. The goal of this proposal is to investigate the regulatory function of XL?s in FGF23 production and its role in diseases with dysregulated FGF23 production. Studying XL?s knockout (XLKO) mice as a model to explore the function of XL?s in humans, we found that XL?s plays a critical role in phosphate homeostasis during early postnatal development. We also showed that XL?s mediates renal PTH actions immediately after birth via the PLC/PKC pathway. Our recent work showed that XL?s ablation results in hyperphosphatemia with significantly reduced serum FGF23. Our preliminary results strongly indicate that XL?s ablation leads to diminished FGF23 and Fgfr1 mRNA levels, as well as reduced PLC/PKC and ERK1/2 signaling in a bone cell-autonomous manner. In addition, our preliminary results show that XL?s ablation mitigates the rise of FGF23 induced by acute kidney injury in mice. Therefore, we hypothesize that XL?s plays a critical role in the production of FGF23 in bone.
In Aim 1, we will determine (a) the role of XL?s/PLC/PKC signaling in FGF23 production, and (b) the mechanism by which XL?s regulates ERK1/2 activation.
In Aim 2, we will test the hypothesis that XL?s contributes to PTH-induced FGF23 production via the PLC/PKC and/or ERK1/2 pathway. We will also address the hypothesis that the interaction of XL?s with SNX9, dynamin, RACK1 and/or IQGAP1 is critical for XL?s- mediated FGF23 production.
In Aim 3, we will determine whether XL?s ablation mitigates the elevated serum FGF23 levels in a mouse model of (a) acute kidney injury and (b) chronic kidney disease. Results of the proposed experiments will provide novel mechanistic insights into the regulation of FGF23 production and will also identify potential drug targets for treating patients with dysregulated FGF23 levels. Moreover, our studies will provide mechanistic insights into the cellular actions of XL?s in bone and enhance the knowledge of its roles in human diseases.

Public Health Relevance

Abnormal action or production of FGF23, a hormone regulating the level of phosphate in our blood, causes or contributes to the development of multiple human disorders. We have found that a protein called XL?s is a previously unrecognized stimulator of FGF23 production. We now aim to elucidate the underlying mechanisms for this action and determine the role of XL?s in the production of excess FGF23 in certain diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK073911-10
Application #
9418592
Study Section
Skeletal Biology Development and Disease Study Section (SBDD)
Program Officer
Malozowski, Saul N
Project Start
2007-08-01
Project End
2020-11-30
Budget Start
2017-12-01
Budget End
2018-11-30
Support Year
10
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02114
Bastepe, Murat (2017) GNAS mutations and heterotopic ossification. Bone :
He, Qing; Bouley, Richard; Liu, Zun et al. (2017) Large G protein ?-subunit XL?s limits clathrin-mediated endocytosis and regulates tissue iron levels in vivo. Proc Natl Acad Sci U S A 114:E9559-E9568
Reyes, Monica; Karaca, Anara; Bastepe, Murat et al. (2017) A novel deletion involving GNAS exon 1 causes PHP1A and further refines the region required for normal methylation at exon A/B. Bone 103:281-286
Bastepe, Murat; Turan, Serap; He, Qing (2017) Heterotrimeric G proteins in the control of parathyroid hormone actions. J Mol Endocrinol 58:R203-R224
Zhu, Yan; He, Qing; Aydin, Cumhur et al. (2016) Ablation of the Stimulatory G Protein ?-Subunit in Renal Proximal Tubules Leads to Parathyroid Hormone-Resistance With Increased Renal Cyp24a1 mRNA Abundance and Reduced Serum 1,25-Dihydroxyvitamin D. Endocrinology 157:497-507
Wentworth, Kelly; Hsing, Alyssa; Urrutia, Ashley et al. (2016) A Novel T55A Variant of Gs ? Associated with Impaired cAMP Production, Bone Fragility, and Osteolysis. Case Rep Endocrinol 2016:2691385
Turan, Serap; Thiele, Susanne; Tafaj, Olta et al. (2015) Evidence of hormone resistance in a pseudo-pseudohypoparathyroidism patient with a novel paternal mutation in GNAS. Bone 71:53-7
Turan, Serap; Bastepe, Murat (2015) GNAS Spectrum of Disorders. Curr Osteoporos Rep 13:146-58
He, Qing; Zhu, Yan; Corbin, Braden A et al. (2015) The G protein ? subunit variant XL?s promotes inositol 1,4,5-trisphosphate signaling and mediates the renal actions of parathyroid hormone in vivo. Sci Signal 8:ra84
Turan, Serap; Fernandez-Rebollo, Eduardo; Aydin, Cumhur et al. (2014) Postnatal establishment of allelic G?s silencing as a plausible explanation for delayed onset of parathyroid hormone resistance owing to heterozygous G?s disruption. J Bone Miner Res 29:749-60

Showing the most recent 10 out of 35 publications